Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04033562 · ClinicalTrials.gov registry record · Phase 4
The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis
A Phase 4 study, sponsored by WellSpan Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT04033562 is a Phase 4 study that was terminated before completion, run by WellSpan Health. The registered enrollment target is 2 participants.
The verdict
NCT04033562, a Phase 4 study, was terminated before completion, sponsored by WellSpan Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Pregnant women with a history of opioid use disorder, chronic opioid use or those who are on medication assisted treatment will be randomly assigned to receive either a sub-fascial continuous infusion of bupivacaine or lidocaine/menthol patch after Cesarean delivery. Post-operative pain scores and opioid usage in the post-operative period will be recorded.
Interventions
- DRUG Lidocaine patch
- DEVICE Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04033562
The ClinicalTrials.gov registry entry for NCT04033562 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WellSpan Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine patch is the first listed.
NCT04033562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04033562 about?
NCT04033562 is a clinical study titled "The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis". Pregnant women with a history of opioid use disorder, chronic opioid use or those who are on medication assisted treatment will be randomly assigned to receive either a sub-fascial continuous infusion of bupivacaine or lidocaine/menthol patch after Cesarean delivery. Post-operative pain scores and o...
What is the current status of trial NCT04033562?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2020-01-15. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT04033562?
The interventions under investigation include: Lidocaine patch (DRUG), Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr (DEVICE).
Who is sponsoring clinical trial NCT04033562?
This trial is sponsored by WellSpan Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.